[go: up one dir, main page]

IN2012DN03817A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03817A
IN2012DN03817A IN3817DEN2012A IN2012DN03817A IN 2012DN03817 A IN2012DN03817 A IN 2012DN03817A IN 3817DEN2012 A IN3817DEN2012 A IN 3817DEN2012A IN 2012DN03817 A IN2012DN03817 A IN 2012DN03817A
Authority
IN
India
Prior art keywords
treatment
biomarkers
inhibitor
proliferative
predict
Prior art date
Application number
Inventor
Denis Drygin
Sean O'brien
Kenna Anderes
Daniel D Vonhoff
John K C Lim
Claire S Padgett
Joshua R Bliesath
Caroline B Ho
William G Rice
Adam Siddiqui-Jain
Original Assignee
Cylene Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals filed Critical Cylene Pharmaceuticals
Publication of IN2012DN03817A publication Critical patent/IN2012DN03817A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/575—
    • G01N33/57515—
    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Disclosed are biomarkers for determining the sensitivity of protein kinase CK2-mediated diseases, such as proliferative and/or inflammatory disorders, to treatment with CK2 inhibitors. These biomarkers can be used to predict or select subjects likely to be responsive to treatment with a CK2 inhibitor, and to treat or monitor subjects undergoing treatment with a CK2 inhibitor.
IN3817DEN2012 2009-10-02 2010-10-04 IN2012DN03817A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24827009P 2009-10-02 2009-10-02
US25580509P 2009-10-28 2009-10-28
US32377110P 2010-04-13 2010-04-13
US38068510P 2010-09-07 2010-09-07
PCT/US2010/051341 WO2011041785A1 (en) 2009-10-02 2010-10-04 Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN03817A true IN2012DN03817A (en) 2015-08-28

Family

ID=43128291

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3817DEN2012 IN2012DN03817A (en) 2009-10-02 2010-10-04

Country Status (11)

Country Link
US (1) US20110212845A1 (en)
EP (1) EP2483686A1 (en)
JP (1) JP2013506836A (en)
KR (1) KR20120104196A (en)
AU (1) AU2010300307A1 (en)
BR (1) BR112012007555B1 (en)
CA (1) CA2776278A1 (en)
IL (1) IL218935A0 (en)
IN (1) IN2012DN03817A (en)
MX (1) MX2012003997A (en)
WO (1) WO2011041785A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212773D0 (en) * 2012-07-18 2012-08-29 Ucl Business Plc Vascular remodelling
US9146545B2 (en) 2012-11-27 2015-09-29 Honeywell International Inc. Multivariable control system for setpoint design
TWI582239B (en) 2013-03-11 2017-05-11 諾華公司 Markers associated with WNT inhibitors
WO2015053452A1 (en) * 2013-10-08 2015-04-16 한국생명공학연구원 Splicing regulator containing cx-4945 as active ingredient
KR101593595B1 (en) * 2013-10-08 2016-02-12 한국생명공학연구원 A splicing regulator comprising CX-4945 as an active ingredient
JP6666848B2 (en) * 2014-02-18 2020-03-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1 / OBR complex signaling pathway
MX375557B (en) * 2014-07-18 2025-03-06 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016133860A1 (en) * 2015-02-16 2016-08-25 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
EP4403581A4 (en) * 2022-03-30 2025-06-18 Miwako Homma ANTI-CK2 ALPHA ANTIBODY OR FRAGMENT THEREOF
CN115160341B (en) * 2022-07-18 2023-07-18 中国医学科学院医学实验动物研究所 Benzoxazine compounds and their medicinal uses
KR102641010B1 (en) * 2023-12-04 2024-02-28 대한민국 Pharmaceutical composition for preventing or treating severe fever with thrombocytopenia syndrome comprising of silmitasertib as an active ingredient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200715636A (en) 2005-10-04 2007-04-16 Antig Tech Co Ltd Method of controlling fuel concentration used in direct liquid fuel cell
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US8488289B2 (en) 2006-09-27 2013-07-16 International Rectifier Corporation Current protection circuit for intelligent power switch
US20090035609A1 (en) 2007-07-31 2009-02-05 Apple Inc. Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices

Also Published As

Publication number Publication date
WO2011041785A1 (en) 2011-04-07
MX2012003997A (en) 2012-07-25
IL218935A0 (en) 2012-07-31
CA2776278A1 (en) 2011-04-07
JP2013506836A (en) 2013-02-28
AU2010300307A1 (en) 2012-05-24
KR20120104196A (en) 2012-09-20
EP2483686A1 (en) 2012-08-08
BR112012007555B1 (en) 2020-09-29
BR112012007555A2 (en) 2016-10-25
US20110212845A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
IN2012DN03817A (en)
WO2015031808A3 (en) Diagnostic methods and compositions for treatment of glioblastoma
PH12012501581A1 (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
MX2012001716A (en) Biological markers for monitoring patient response to vegf antagonists.
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
MX2010006854A (en) Biomarkers for sensitivity to anti-igf1r therapy.
HK1208470A1 (en) Biomarkers for use in integrin therapy applications
BR112013030606A2 (en) biomarkers for hedgehog inhibitor therapy
DK1846424T3 (en) Proteasome inhibitors and methods for their use
MX2014001246A (en) Identification of gene expression profile as a predictive biomarker for lkb1 status.
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
CO6680668A2 (en) Biomarker assays to detect or measure inhibition of tor kinase activity
WO2015172085A3 (en) Biomarkers for response to pi3k inhibitors
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
TR201907241T4 (en) Lipocalin as a biomarker for IL-17 inhibitor therapy efficacy 2.
MX2015009392A (en) Anti-tnf and anti-il17 combination therapy biomarkers for inflammatory disease.
PH12019501942A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
UA118658C2 (en) Diagnostic method for predicting response to tnf? inhibitor
EA201171178A1 (en) DEVICE AND METHOD FOR DETERMINATION AND QUANTITATIVE ANALYSIS OF ANALYSIS, IN PARTICULAR, MYCOTOXINS
MX384423B (en) BIOMARKERS FOR RESPONSE TO ZESTE HOMOLOGUE 2 ENHANCER (EZH2) INHIBITORS.
MX367312B (en) Inhibitor of igfbp3/tmem219 axis and diabetes.
MX340392B (en) Braf mutations conferring resistance to braf inhibitors.
WO2012068464A3 (en) Methods of treating and preventing thrombotic diseases using ask1 inhibitors
WO2015049390A3 (en) Kidney disease biomarker
MX2012000509A (en) Biomarker for selecting patients and related methods.